NeuroOne Medical Technologies
NMTC
20 hedge funds and large institutions have $4.52M invested in NeuroOne Medical Technologies in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 3 closing their positions.
2,200% more call options, than puts
Call options by funds: $23K | Put options by funds: $1K
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
94% more capital invested
Capital invested by funds: $2.33M → $4.52M (+$2.19M)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
5% more funds holding
Funds holding: 19 → 20 (+1)
0.17% more ownership
Funds ownership: 1.82% → 1.99% (+0.17%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$587K |
| 2 |
WAAG
Wealth Alliance Advisory Group
Wichita,
Kansas
|
+$23.9K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$23.2K |
| 4 |
VF
Virtu Financial
New York
|
+$22.2K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$12.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$201K |
| 2 |
SG Americas Securities
New York
|
-$45K |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$44.1K |
| 4 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$2.12K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$435 |
NMTC Hedge Fund Activity: Q4 2023 in Review
20 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in NeuroOne Medical Technologies (NMTC) for Q4 2023, worth a combined $4.52M — up 94% from $2.33M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new NMTC positions and 3 closed out — a net gain of 1 holder — while 7 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $587K. The largest seller was Walleye Capital, exiting entirely with an estimated $201K sold.
- 20 institutional investors held NeuroOne Medical Technologies (NMTC) as of Q4 2023, up from 19 in Q3 2023.
- Funds reported $4.52M of NeuroOne Medical Technologies stock for Q4 2023, up 94% quarter-over-quarter.
- 4 funds opened new NeuroOne Medical Technologies positions in Q4 2023 and 3 closed out, a net change of +1 holder.
- The largest NeuroOne Medical Technologies buyer in Q4 2023 was Vanguard Group, an estimated $587K added.
- The largest NeuroOne Medical Technologies seller in Q4 2023 was Walleye Capital, an estimated $201K sold.
Based on aggregated 13F filings for Q4 2023.